Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News ACADIA Pharmaceuticals Inc ACAD

Healthcare Biotechnology
Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:ACAD)

Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences

Business Wire 12 hours ago

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire 6 days ago

Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview

Business Wire November 6, 2024

Acadia Pharmaceuticals Enters Into an Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Business Wire November 5, 2024

Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024

Business Wire October 17, 2024

Acadia Pharmaceuticals Announces Health Canada Approval of DAYBUE(TM) (trofinetide) for the Treatment of Rett Syndrome

Business Wire October 16, 2024

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 8, 2024

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire September 26, 2024

Catherine Owen Adams Succeeds Steve Davis as CEO of Acadia Pharmaceuticals

Business Wire September 23, 2024
View More News ››

Opinion & Analysis (NDAQ:ACAD)

Embrace low-cap biotech for high gains: Eden Rahim of Next Edge Capital

The Life Sciences Report March 2, 2016

Use stock volatility to invest in innovative oncology companies: JMP Security's Michael King Jr.

Gail Dutton October 15, 2015

The Calandra Report: Watch this hot tub!

Thom Calandra January 10, 2014
View More Opinion ››

Bullboard Posts (NDAQ:ACAD)

Acadia Pharmaceuticals to Participate in the Canaccord Genui

Breaking News: $ACAD Acadia Pharmaceuticals to Participate in the Canaccord Genuity 44th Annual Growth ConferenceAcadia Pharmaceuticals...
whytestocks - August 7, 2024

ACADIA PHARMACEUTICALS: WHAT’S NEXT AFTER THE NEGATIVE FDA A

$ACAD Acadia Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company developing small molecule drugs for treating central...
AviseAnalytics - June 22, 2022

FDA Approves ACADIA Pharmaceuticals - Parkinson's Disease

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative...
DaveInCalgary - April 30, 2016

RE:RE: Long Term Hold?

Their PD product, pimavanserin, is on an expedited path to an NDA filing and their balance sheet is looking good. Great potential. Very...
captcanuck - August 9, 2013

RE: Long Term Hold?

That's a heavy blow to have discover the product is no better than what is already out there, or more importantly no different. If...
amy89 - June 21, 2008

RE: Long Term Hold?

Although it has the ability to tap into the aging baby-boomers market, it has to get to the market first. Its schizophrenia drug had...
gossipgirl - June 20, 2008
View more Bullboard ››

EnviroGold Global Limited.

EnviroGold Global Limited.

EnviroGold Global Limited is a Canadian headquartered clean technology company with a global vision and a strategic focus ...
View More »